Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label liver cancer/sorafenib. Show all posts
Showing posts with label liver cancer/sorafenib. Show all posts
Thursday, November 29, 2018

Balancing Efficacy With Toxicity Among the Agents for HCC

›
Balancing Efficacy With Toxicity Among the Agents for HCC Catherine Frenette, MD Published Online:Nov 29, 2018 Catherine Frenette, MD:...
Monday, October 15, 2018

Liver Cancer Treatment Paradigm Undergoing Major Overhaul

›
Liver Cancer Treatment Paradigm Undergoing Major Overhaul Christine Lehmann, MA Published Online: Oct 15,2018 Until recently, few s...
Saturday, April 22, 2017

SIRT is better tolerated than sorafenib, but doesn't increase overall survival in HCC

›
Meeting Updates Updates On This Blog SIRT is better tolerated than sorafenib, but doesn't increase overall survival in HCC          ...
Monday, February 20, 2017

Sorafenib benefit dependent on hepatitis status in patients with HCC

›
Sorafenib benefit dependent on hepatitis status in patients with HCC February 19, 2017 Sorafenib improved OS among patients with hepat...
Saturday, January 7, 2017

Meta-analysis/Effect of sorafenib for advanced liver cancer dependent on patients’ hepatitis status

›
Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase I...
Thursday, October 25, 2012

The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma

›
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma R. Cabrera * , A. R. Limaye, P. Horne, R. Mills, C...
Monday, July 23, 2012

Combination of Tarceva, Nexavar fails to meet main goal of Phase III liver cancer study

›
July 23, 2012 Combination of Tarceva, Nexavar fails to meet main goal of Phase III liver cancer study Last Updated:July 23, 2012 07:36 ...
Wednesday, July 11, 2012

Sorafenib beneficial in liver cancer regardless of etiology

›
By David Douglas NEW YORK (Reuters Health) – Sorafenib improves survival and disease control consistently in patients with advanced hep...
Wednesday, April 20, 2011

Positive Clinical Data of JX-594 in Combination W-Sorafenib in Advanced Liver Cancer

›
Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer S...
1 comment: